# Quality Evaluation — Yeast-Expressed Human OPN Recommended Cell Assays

**Report:** `report.md`  
**Date:** 2026-06-26  
**Mode:** standard

---

## Red-line check

- [ ] Fabricated citation  
- [ ] Company-only key claim  
- [ ] Unresolved internal contradiction  
- [ ] Empty section  
- [ ] Validation gate failed 3x  

**Triggered:** None

---

## Total score

**32/35**

The report is decision-ready: sources are traceable, the assay rationale is anchored to regulatory precedent, contradictions are flagged, and the structure follows the skill template. Minor room for improvement remains in analytical depth and visual support.

---

## Dimension scores

| Dimension | Score | Notes |
|-----------|-------|-------|
| D1 Source traceability | 5/5 | All 32 citations resolve to `sources.jsonl`; every source has a URL/PMID/patent number; official sources used for regulatory claims. |
| D2 Evidence quality | 4/5 | Strong use of EFSA/FDA/peer-reviewed sources; some cell-assay recommendations are extrapolated from bmOPN/native OPN because no yeast-expressed hOPN data exist. This is flagged honestly. |
| D3 Domain fit | 5/5 | Threads matched the project type (protein, cell assay, regulatory); no irrelevant cosmetic-only sections; sub-mode logic appropriate. |
| D4 Structural completeness | 5/5 | All template sections present; executive summary reflects body; recommendations and risks are specific. |
| D5 Analytical depth | 4/5 | Good trade-off discussion and context-dependency analysis; could add more quantitative benchmarking (e.g., expected fold-change thresholds for assays). |
| D6 Format & readability | 5/5 | Consistent `#` headings, `-` bullets, no `*` bullet mixing; tables readable; English clear. `validate_report.py` passed. |
| D7 Deliverable completeness | 4/5 | `report.md`, `report.docx`, `sources.jsonl`, validation output all present. Optional SVG chart not generated for this validation run. |

---

## Priority fixes

1. **Add quantitative success criteria** for each assay (e.g., minimum TEER recovery, cytokine fold-change, HA IC₅₀ ratio vs. reference) when the literature supports them.
2. **Generate one priority-tier chart** (bar or timeline) for visual summary in standard/deep mode.
3. **Verify one high-value URL** manually: FDA GRN 716 inventory page occasionally redirects; ensure the cited link resolves.

---

## [待补充] / To be verified

- Direct yeast-expressed hOPN cell-assay data remain unpublished; all functional claims are extrapolated.
- FSANZ status for bmOPN remains unconfirmed in this search.
- Optimal phosphorylation stoichiometry for yeast-expressed hOPN is not established.
